Quantum Leap Healthcare Collaborative
search

"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM
Close
Close
I-SPY Email List Sign-up
I-SPY  PATIENT INFORMATION SITE. Visit: www.ispypatient.org
Perlmutter J, Brain S, Brown T, et al.
Advocate involvement in Clinical Trials: Lessons from the Patient-centric I-SPY2 Breast Cancer Trial
.
Med Res Arch
11 (7.2)
:
2023
.
abstract
pdf
doi
Perlmutter J, Brain S, Brown T, et al.
Advocate involvement in Clinical Trials: Lessons from the Patient-centric I-SPY2 Breast Cancer Trial
. In 
 (Eds.), 
Med Res Arch
11 (7.2)
(
); pp.
2023
.
abstract
pdf
link
Boughey JC, Yu H, Dugan CL, et al.
Changes in Surgical Management of the Axilla Over 11 Years – Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial
.
Ann Surg Oncol
(published online)
:
1-10
2023
.
abstract
pdf
doi
Boughey JC, Yu H, Dugan CL, et al.
Changes in Surgical Management of the Axilla Over 11 Years – Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial
. In 
 (Eds.), 
Ann Surg Oncol
(published online)
(
); pp.
1-10
2023
.
abstract
pdf
link
Mukhtar RA, Chau H, Woriax H, et al.
Breast Conservation Surgery and Mastectomy have Similar Locoregional Recurrence Following Neoadjuvant Chemotherapy: Results from 1,462 Patients on the Prospective, Randomized I-SPY2 Trial
.
Ann Surg
(published ahead of print)
:
2023
.
abstract
pdf
doi
Mukhtar RA, Chau H, Woriax H, et al.
Breast Conservation Surgery and Mastectomy have Similar Locoregional Recurrence Following Neoadjuvant Chemotherapy: Results from 1,462 Patients on the Prospective, Randomized I-SPY2 Trial
. In 
 (Eds.), 
Ann Surg
(published ahead of print)
(
); pp.
2023
.
abstract
pdf
link

Featured News

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.

>2500
patients enrolled
25
agents completed
evaluation since 2010
3
agents received
accelerated approval
Find out more

World-class science requires world-class scientists

Meet some of our team

I-SPY is supported by:

I-SPY Sponsor:
Quantum Leap Healthcare Collaborative